M
Mitosense is developing targeted therapies for neurodegenerative diseases by utilizing advanced gene editing techniques to modify cellular pathways associated with neurodegeneration. The company aims to improve patient outcomes by addressing the underlying biological mechanisms that lead to cognitive decline and motor function loss.
Updated 20 months ago
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CC
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Mitosense is developing targeted therapies for neurodegenerative diseases by utilizing advanced gene editing techniques to modify cellular pathways associated with neurodegeneration. The company aims to improve patient outcomes by addressing the underlying biological mechanisms that lead to cognitive decline and motor function loss.